NFKB1 and cancer: Furthermore, treatment with the cancer drug cisplatin, which induces DNA-damage through DNA cross-linking, revealed that in the same U-2 OS osteosarcoma cell line used for the analysis of the other compounds, no induction of NF-κB DNA-binding occurred.